Rescue Therapies for Asthma

Target Audience 

The educational design of this activity addresses the needs of clinicians who manage patients with asthma, including pulmonologists and allergists/clinical immunologists. 

Series Description 

Although asthma treatments are widely available, between one-third and one-half of patients continue to have symptoms that regularly interfere with everyday life. These asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year, which often lead to inpatient hospital stays. Thus, there is a clear need for ongoing education about asthma management, particularly when there are significant changes in treatment recommendations or therapeutic options. In this Hot Topics series, an expert faculty will provide focused education on: 1) best practices for assessing asthma control, 2) the latest evidence regarding new rescue inhaler therapies, and 3) updates to recommendations for as-needed inhaler therapy use. Utilizing an engaging delivery format that combines graphics and video, this educational series meets the needs of busy clinician learners who wish to stay current on the evolving asthma treatment landscape. 

Educational Objectives  

After completing this activity, the participant should be better able to: 

1. Describe the clinical profiles and trial data for new combination rescue inhaler therapies in patients with asthma

Physician Accreditation Statement 

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physician Credit Designation 

Integritas designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Integritas Contact Information 

For more information about the approval of this program, please contact Integritas at info@exchangecme.com.  

Instructions to Receive Credit 

In order to receive credit for this activity, the participant must: 

1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity. 
2. Complete the Preactivity Questions. 
3. Review the activity content. 
4. Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.   

Fee Information & Refund/Cancellation Policy 

There is no fee for this educational activity.

Disclosures of Conflicts of Interest 

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

BradleyE. Chipps, MD - Consulting Fees: AstraZeneca plc, Boehringer Ingelheim International GmbH, Genentech, Inc., GSK plc, Novartis AG, Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme

The Integritas Communication planners and managers have no relevant financial relationships to disclose. 

Disclosure of Unlabeled Use 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.